Evidence map›Paper›PMID 37461056›Full record

ArticleEuropean journal of medical research2023

Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.

Bin Lang, Chen Cao, Xiaoxiao Zhao, Yi Wang, Ying Cao, Xueying Zhou, Tong Zhao, Yuyan Wang, Ting Liu, Wenjia Liang and 4 more

Erratum issuedAbstract read
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Bin Lang *Peking University Health Science Center-Macao Polytechnic University Nursing Academy, Macao Polytechnic University, Macao, 999078, China.
Chen Cao *Department of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Xiaoxiao Zhao *Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Yi Wang *Operating Room, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Ying Cao *Department of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Xueying Zhou *Department of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Tong ZhaoDepartment of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Yuyan WangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510000, Guangdong, China.
Ting LiuDepartment of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Wenjia LiangDepartment of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Zheng HuDepartment of Obstetrics and Gynecology, Women and Children's Hospital Affiliated to Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Xun TianDepartment of Obstetrics and Gynecology, Academician Expert Workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China. tianxun@zxhospital.com.
Jingjing ZhangDepartment of Gynecology and Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430062, Hubei, China. zhangjingjinggangda@126.com.
Yongji YanDepartment of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China. 7577yyj@163.com.

Funding

General Program of Natural Science Foundation of Guangdong Province of China 2021A1515012438Guangdong Basic and Applied Basic Research Foundation 2020A1515110170National Natural Science Foundation of China 32171465the Initiation Research Fee for Special Talent Introduction of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine 2014RCthe National Ten Thousand Plan-Young Top Talents of China 80000-41180002
6 · The paper itself

Abstract

backgroundHuman papillomavirus (HPV) has been proposed as a potential pathogenetic organism involved in prostate cancer (PCa), but the association between HPV infection and relevant genomic changes in PCa is poorly understood.

methodsTo evaluate the relationship between HPV genotypes and genomic alterations in PCa, HPV capture sequencing of DNA isolated from 59 Han Chinese PCa patients was performed using an Illumina HiSeq2500. Additionally, whole-exome sequencing of DNA from these 59 PCa tissue samples and matched normal tissues was carried out using the BGI DNBSEQ platform. HPV infection status and genotyping were determined, and the genetic disparities between HPV-positive and HPV-negative PCa were evaluated.

resultsThe presence of the high-risk HPV genome was identified in 16.9% of our cohort, and HPV16 was the most frequent genotype detected. The overall mutational burden in HPV-positive and HPV-negative PCa was similar, with an average of 2.68/Mb versus 2.58/Mb, respectively, in the targeted whole-exome region. HPV-negative tumors showed a mutational spectrum concordant with published PCa analyses with enrichment for mutations in SPOP, FOXA1, and MED12. HPV-positive tumors showed more mutations in KMT2C, KMT2D and ERCC2. Copy number alterations per sample were comparable between the two groups. However, the significantly amplified or deleted regions of the two groups only partially overlapped. We identified amplifications in oncogenes, including FCGR2B and CCND1, and deletions of tumor suppressors, such as CCNC and RB1, only in HPV-negative tumors. HPV-positive tumors showed unique deletions of tumor suppressors such as NTRK1 and JAK1.

conclusionsThe genomic mutational landscape of PCa differs based on HPV infection status. This work adds evidence for the direct involvement of HPV in PCa etiology. Different genomic features render HPV-positive PCa a unique subpopulation that might benefit from virus-targeted therapy.

Indexed as

Papillomavirus InfectionsProstatic NeoplasmsEast Asian PeopleGenomicsGenotypeHumansMaleNuclear ProteinsRepressor ProteinsXeroderma Pigmentosum Group D ProteinERCC2 protein, humanNuclear ProteinsRepressor ProteinsSPOP protein, humanXeroderma Pigmentosum Group D ProteinCapture sequencingHuman papillomavirusProstate cancerWhole-exome sequencing

Identifiers

PMID37461056
PMCPMC10351112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.